Opinion|Videos|December 16, 2024
Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits
Panelists discuss how disease-modifying therapies (DMTs) like dimethyl fumarate, fingolimod, and cladribine demonstrate potential blood-brain barrier penetration, offering neuroprotective mechanisms. While these therapies show promise in mitigating cognitive decline, their impacts vary, highlighting the complex interplay among neuroinflammation, immune modulation, and cognitive preservation in multiple sclerosis management.
Advertisement
Video content above is prompted by the following:
- Which of the DMTs can penetrate the blood-brain barrier and have the potential to impact brain health directly?
- What is our understanding of the impact of various DMTs on cognitive health?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits
3
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
4
Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy
5